<DOC>
	<DOC>NCT03002233</DOC>
	<brief_summary>This study is a 2-part study. Part A is a single-dose, open-label study design to determine the PK, safety and tolerability of 5 μg TRK-820 oral administration in subjects with end-stage renal disease (ESRD) who require hemodialysis. Part B is a multiple dose, open-label study design to determine the PK, PD, safety and tolerability of multiple doses in subjects with ESRD who require hemodialysis with refractory uremic pruritus (UP). Each subject will receive 3 doses of TRK-820 (2.5, 5 and 10 μg).</brief_summary>
	<brief_title>TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>Adult nonsmoking male and female subjects (≥ 18 years of age) who have ESRD requiring hemodialysis, at least 3 times a week. Subjects has a clinical diagnosis of UP, which is uncontrolled by current medications or treatments.(Part B only) Subject has a known hypersensitivity to opioids or the ingredients of the study medication. Subject has pruritus other than related to ESRD (i.e., UP).(Part B only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>TRK-820</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Uremic Pruritus</keyword>
</DOC>